Table 2.
Solitary versus Multifocal Brain Biopsy-Confirmed TDL presenting as a first lifetime neurological event.
| Solitary TDL (n=10) |
Multifocal Lesions (n=8) |
||
|---|---|---|---|
| Demographics | |||
| Age in years, mean (SD) | 45.9 (18.1) | 36.8 (13.9) | ns |
| Sex (%female) | 30% | 75% | P=0.15 |
| Radiographic Features | |||
| Enhancement n(%) | 10 (100%) | 8 (100%) | |
| Edema n(%) | 10 (100%) | 5 (62.5%) | P=0.07 |
| Spinal Lesions n(%) | 1 (12.5%) | 2 (28.6%) | ns |
| Laboratory Features | |||
| CSF Studies | |||
| Elevated IgG/OCB n(%) | 0 (0%) | 4 (66.7%) | P=0.06 |
| WBC (cells/µL) mean (SD) | 11.2 (21.7) | 10 (11.7) | ns |
| Protein (mg/dL) mean (SD) | 102 (75.6) | 39.1 (13.0) | P=0.04* |
| Glucose (mg/dL) mean (SD) | 70 (32.6) | 62.5 (18.9) | ns |
| Treatment n (%) | |||
| IV Methylprednisolone | 3 (30%) | 7 (87.5%) | P=0.02* |
| Plasma Exchange | 2 (20%) | 5 (62.5%) | ns |
| MS Disease Modifying Therapy | 2 (28.6%) | 7 (87.5%) | P=0.04* |
| Prognosis | |||
| Median follow-up duration in months | 20 | 24 | ns |
| Clinical Relapse n(%) | 2 (28.6%) | 2 (33.3%) | ns |
| MRI Progression n(%) | 4 (40%) | 3 (42.9%) | ns |
| Last EDSS, mean (SD) | 2.8 (2.3) | 3.6 (2.7) | ns |